Tests a CAR-T cell therapy for multiple myeloma with kidney problems
Tests a BCMA-targeted CAR-T cell therapy in people with myeloma and kidney impairment.
Plain-language title generated from the registry record
Registry title: Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Where in China
- Chinese PLA General HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Daihong Liu
- Trial code
- NCT07489534
- Record updated
- 24 March 2026
- Original description
The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal dysfunction.Read full original descriptionShow less
Exploratory Clinical Study on PD-1Ab21-BCMA CAR-T Cells (CD203) for First-line Consolidation Therapy of Multiple Myeloma With Renal Dysfunction
The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal dysfunction.
Inclusion: Age: Over 14 years old; Diagnosed with multiple myeloma accompanied by renal dysfunction, received ≥ 2 courses of clinical first-line treatment, evaluated efficacy above PR, and predicted survival of more than three months; The hospital examination meets the following indicators:; ECOG physical status score 0-2 or KPS score>80 points; Having sufficient venous access for single or intravenous blood collection, and no other blood cells Separation contraindications; WBC≥1×109/L，LY≥0.3×109/L，; ALT and AST ≤ 2.5 ULN; Serum total bilirubin ≤ 2.0mg/dL (34.2 μmol/L); PT:INR<1.7 or PT prolonged by<4s compared to normal value.
Exclusion: Within 2 weeks prior to signing the informed consent form, systemic use of steroid drugs (inhalable steroids may be used); The patient needs anticoagulant therapy (such as warfarin or heparin); The patient requires long-term antiplatelet therapy (aspirin, dose>300mg/d); Clopidogrel, dose>75mg/d); Additionally,; Any uncontrollable active infection; Presence of active hepatitis B or C virus infection; HIV/AIDS infection; Has neurological disorders; Allergies to immunotherapy and related drugs; Currently, there are patients with heart disease or poorly controlled hypertension who require treatment; Currently, patients with unstable or active ulcers or gastrointestinal bleeding; Patients with a history of organ transplantation or waiting for organ transplantation; Pregnant or lactating women (the safety of this treatment for unborn babies is unknown, and the assessment of pregnancy status for female participants is negative in serum or urine pregnancy tests within 48 hours prior to infusion); Hyponatremia, blood sodium<125mmol/L; Baseline blood potassium<3.5mmol/L (potassium can be supplemented before participating in the study to restore blood potassium levels above this level); Patients currently participating in other clinical trials; Researchers believe that other reasons are not suitable for clinical trial participants.